VTV Therapeutics has initiated its Phase 3 CATT1 trial, evaluating cadisegliatin as an oral adjunctive therapy to insulin for adults with type 1 diabetes (T1D). Topline results are anticipated in the latter half of 2026. This trial marks a pivotal moment for VTV, pushing their lead candidate further into late-stage development and potentially addressing a significant unmet need in T1D management. The question remains: can an oral therapy genuinely disrupt the T1D landscape, long dominated by insulin injections and device innovation?
The trial’s focus on reducing hypoglycemic events underscores a critical challenge in T1D management. Tight glycemic control often comes at the cost of increased hypoglycemia risk, a constant balancing act for patients and clinicians. If cadisegliatin, a liver-selective glucokinase activator, proves effective in mitigating this risk while improving overall glycemic control, it could represent a significant advancement in T1D care. This has important implications not just for patients but also for payers, who bear the significant costs associated with hypoglycemic episodes and their long-term consequences.
This move by VTV also reflects a broader trend in diabetes management: a shift towards oral therapies that offer increased patient convenience and potentially better adherence. The market is already witnessing the success of GLP-1 receptor agonists, both injectable and oral, in T2D and increasingly in obesity. VTV’s pursuit of an oral T1D therapy positions them to capitalize on this preference for less invasive treatment options. It also highlights the intensifying competition within the diabetes space, where pharmaceutical companies are vying for market share by targeting specific patient needs and unmet medical demands.
The CATT1 trial will be closely watched by endocrinologists, diabetes educators, and payers. The use of continuous glucose monitors (CGMs) to assess the primary endpoint further highlights the growing importance of real-world data in evaluating treatment efficacy and informing clinical decision-making. Positive results could pave the way for a new class of oral T1D therapies, potentially reshaping the treatment paradigm and offering patients a much-needed alternative to intensive insulin regimens. However, the ultimate success of cadisegliatin hinges not only on demonstrating clinical efficacy and safety but also on securing payer reimbursement in a value-driven healthcare landscape. The question remains: will the potential benefits of reduced hypoglycemia and improved glycemic control translate into sufficient value for payers to justify adoption?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
